Harmine Hydrochloride Mediates the Induction of G2/M Cell Cycle Arrest in Breast Cancer Cells by Regulating the MAPKs and AKT/FOXO3a Signaling Pathways

cell cycle pathway, Harmine Hydrochloride Mediates the Induction of G2/M Cell Cycle Arrest in Breast Cancer Cells by Regulating the MAPKs and AKT/FOXO3a Signaling Pathways
Breast most cancers (BC) is without doubt one of the most typical causes of demise amongst ladies worldwide. Just lately, curiosity in novel approaches for BC has elevated by creating new medicine derived from pure merchandise with decreased unwanted effects. This examine aimed to deal with BC cells with harmine hydrochloride (HMH) to establish its anticancer results and mechanisms.
HMH therapy suppressed cell development, migration, invasion, and colony formation in MCF-7 and MDA-MB-231 cells, whatever the hormone signaling. It additionally decreased the phosphorylation of PI3K, AKT, and mTOR and elevated FOXO3a expression. Moreover, HMH therapy elevated p38 phosphorylation in MCF-7 cells and activated c-Jun N-terminal kinase (JNK) phosphorylation in MDA-MB-231 cells in a dose-dependent method, the place activated p38 and JNK elevated FOXO3a expression.
Activated FOXO3a elevated the expression of p53, p21, and their downstream proteins, together with p-cdc25, p-cdc2, and cyclin B1, to induce G2/M cell cycle arrest. Moreover, HMH inhibited the PI3K/AKT/mTOR pathway by considerably decreasing p-AKT expression together with LY294002, an AKT inhibitor. These outcomes point out that mitogen-activated protein kinases (MAPKs) and AKT/FOXO3a signaling pathways mediate the induction of cell cycle arrest following HMH therapy. Subsequently, HMH may very well be a possible energetic compound for anticancer bioactivity in BC cells.

Diosmetin inhibits cell development and proliferation by regulating the cell cycle and lipid metabolism pathway in hepatocellular carcinoma

Diosmetin (DSM), a newly found pure flavonoid, present in citrus crops and olive leaves, has been reported to inhibit the development of most cancers when used as a meals complement. This examine aimed to research DSM’s anti-hepatocellular carcinoma (HCC) properties and potential molecular mechanisms. Hep3B and HCCLM3 cells have been chosen to judge the anti-HCC properties of DSM in vitro. RNA sequencing (RNA-seq) was used to establish the potential molecular targets and pathways.
Gasoline chromatography-mass spectrometry (GC-MS) was used to judge the impact of DSM therapy on the first metabolites of HCCLM3 cells. Tumor xenograft was carried out in nude mice to look at the anti-HCC properties of DSM in vivo. The outcomes confirmed that DSM inhibited the proliferation and migration of HCC cells in vitro in a dose-dependent method.
RNA-seq recognized 4459 differentially expressed genes (DEGs) that have been extremely enriched within the cell cycle pathway. As well as, DSM regulated cell development by arresting the cell cycle within the G1 part by lowering the expression of BCL2, CDK1, and CCND1. Moreover, metabolomics evaluation revealed that DSM interfered with the lipid metabolism pathway of HCC cells by considerably inhibiting the synthesis of metabolites, comparable to acetic acid, decanoic acid, glycerol, and L-proline.
Subcutaneous tumor formation experiments revealed that DSM considerably decreased the tumor quantity and weight when in comparison with the management. Immunohistochemical evaluation additional revealed that DSM therapy considerably decreased the expression of the proliferative marker KI67. Our findings demonstrated that DSM exhibited antitumor results on HCC cells by inhibiting cell proliferation by way of cell cycle arrest and interfering with lipid metabolism.

Myricetin Induces Autophagy and Cell Cycle Arrest of HCC by Inhibiting MARCH1-Regulated Stat3 and p38 MAPK Signaling Pathways

Myricetin is a kind of pure flavonol recognized for its anticancer exercise. Nevertheless, the molecular mechanism of myricetin in anti-hepatocellular carcinoma (HCC) will not be nicely outlined. Earlier research indicated that downregulation of membrane-associated RING-CH finger protein 1 (MARCH1) contributed to the therapy of a wide range of cancers.
Whether or not the anticancer property of myricetin is related to MARCH1 expression stays to be investigated. This analysis explored the anti-HCC mechanism of myricetin. Our outcomes point out that myricetin induces autophagy and arrests cell cycle on the G2/M part to suppress the proliferation of HCC cells by downregulating MARCH1. Myricetin reduces MARCH1 protein in Hep3B and HepG2 cells. Curiously, myricetin upregulates the MARCH1 mRNA stage in Hep3B cells however downregulates it in HepG2 cells.
The knockdown of MARCH1 by siRNAs (small interfering RNAs) decreases the phosphorylated p38 MAPK (p-p38 MAPK) and Stat3 (p-Stat3), and inhibits HCC cell viability. Furthermore, myricetin inhibits p38 MAPK and Stat3 signaling pathways by downregulating MARCH1 to repress HCC development each in vitro and in vivo. Bafilomycin A1 (BafA1), an autophagy inhibitor, has synergetic impact with myricetin to inhibit HCC development.
Taken collectively, our outcomes reveal that myricetin inhibits the proliferation of HCC cells by inhibiting MARCH1-regulated p38 MAPK and Stat3 signaling pathways. This analysis offers a brand new molecular mechanism for myricetin in anti-HCC and means that focusing on MARCH1 may very well be a novel therapy technique in creating anticancer therapeutics.

Delphinidin induces cell cycle arrest and apoptosis in HER-2 optimistic breast most cancers cell traces by regulating the NF-κB and MAPK signaling pathways

Delphinidin is an anthocyanidin monomer, generally present in greens and fruits, and has demonstrated antitumor results within the HER-2-positive MDA-MB-453 breast most cancers cell line, with low cytotoxicity on regular breast cells. Nevertheless, the direct purposeful mechanisms underlying the impact of delphinidin on HER-2-positive breast most cancers cells has not been absolutely characterised.
Within the current examine, it was discovered that delphinidin may induce G2/M part cell cycle arrest by inhibiting the protein expression stage of cyclin B1 and Cdk1 in HER-2-positive breast most cancers cell traces. As well as, delphinidin promoted the mitochondrial apoptosis pathway by inhibiting the ERK and NF-κB signaling pathway and activating the JNK signaling pathway.
Subsequently, delphinidin markedly suppressed the viability of the HER-2-positive breast most cancers cell traces by modulating the cell cycle and inducing apoptosis. Total, the findings from the current examine demonstrated that delphinidin therapy may induce the mitochondrial apoptosis pathway in human HER-2-positive breast most cancers cell traces, offering an experimental foundation for the prevention and therapy of HER-2-positive breast most cancers by flavonoids.

Dioscin Decreases Breast Most cancers Stem-like Cell Proliferation by way of Cell Cycle Arrest by Modulating p38 Mitogen-activated Protein Kinase and AKT/mTOR Signaling Pathways

Dioscin (DS), a steroidal saponin, has been proven to have anti-cancer exercise by exerting antioxidant results and inducing apoptosis. Nevertheless, the anti-cancer exercise of DS in breast cancer-derived stem cells continues to be controversial.
The aim of this examine was to judge the results of DS on migration, invasion, and colony formation in MDA-MB-231 and MCF-7 cell traces and the mechanism by which it inhibits proliferation of breast most cancers stem-like cells after inducing differentiation into breast most cancers stem cells. DS therapy considerably decreased mobile migration, invasion, and colony formation in MDA-MB-231 and MCF-7 cells.
cell cycle pathway, Harmine Hydrochloride Mediates the Induction of G2/M Cell Cycle Arrest in Breast Cancer Cells by Regulating the MAPKs and AKT/FOXO3a Signaling Pathways
Throughout the differentiation course of that induced manifestation of breast most cancers stem-like cells, DS considerably inhibited mammosphere formation in a dose-dependent method and elevated the expression of p53 and p21 in breast most cancers stem-like cells, decreasing the expression of cdc2 and cyclin B1 in MDA-MB-231 cells and cyclin D, cyclin E, CDK4, and CDK2 in MCF-7 cells.

Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway)

60520 2 vials
EUR 2175
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β-catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter.

GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway)

79041 2 vials
EUR 1810
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene.

TGF/SMAD Signaling Pathway SBE Reporter - HEK293 Cell Line

60653 2 vials
EUR 2505
Description: The SBE Reporter - HEK293 Cell Line is designed for monitoring the activity of the TGF /SMAD signaling pathway. The transforming growth factor beta (TGF ) signaling pathway is involved in a diverse range of cell processes such as differentiation, cell cycle arrest, and immune regulation. TGF signaling has been linked to cardiac disease, cancer, Alzheimer's and other human diseases. TGF proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to phosphorylation and activation of SMAD2 and SMAD3, which then form a complex with SMAD4. The SMAD complex then translocates to the nucleus and binds to the SMAD binding element (SBE) in the nucleus, leading to transcription and expression of TGF / SMAD responsive genes.

IDO Pathway inhibitor

2746-250 each
EUR 392.4

IDO Pathway inhibitor

2746-50 each
EUR 144

TCF/LEF StemBright™ Luciferase iPS Cell Pool (Wnt Pathway)

78515 2 vials
EUR 8500
Description: The TCF/LEF (T-cell factor/lymphoid enhancing factor) StemBright™ Luciferase Cells contain a firefly luciferase gene under the control of TCF/LEF responsive elements, stably integrated into induced Pluripotent Stem (iPS) cells. TCF/LEF transcription factors are downstream of the Wnt signaling pathway. This cell pool is validated for its response to GSK3β inhibitor CHIR-99021, which activates the Wnt signaling pathway in human pluripotent stem cells.

Notch Signaling Pathway Notch1/CSL Reporter - HEK293 Cell Line

60652 2 vials
EUR 2175
Description: The Notch CSL Reporter - HEK293 cell line contains the firefly luciferase gene under the control of Notch-response elements (CSL responsive elements) alone with expression construct for Notch1 E (NOTCH1 that has a deletion of the entire extracellular domain) stably integrated into HEK293 cells. Inside the cells, the Notch1 E can be cleaved by γ-secretase. The active Notch1 NICD is released to nucleus and induces the constitutive expression of luciferase reporter. The cell line is validated for the inhibition of the expression of luciferase reporter using a known inhibitor of the Notch signaling pathway.

CRE/CREB Reporter (Luc) - Jurkat Cell Line (cAMP/PKA Signaling Pathway)

79636 2 vials
EUR 1810
Description: The CRE/CREB Reporter (Luc) - Jurkat Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into Jurkat cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. This cell line is validated for response to stimulation by Forskolin.

CRE/CREB Reporter (Luc) - HEK293 Cell Line (cAMP/PKA Signaling Pathway)

60515 2 vials
EUR 2070
Description: The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line is designed for monitoring the activity of the cAMP/ PKA signaling pathway. The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into HEK293 cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase.

Human Notch Signaling Pathway

HNOT-I 1 set
EUR 657.6

AP1 Reporter Kit (JNK Pathway)

60612 500 rxns.
EUR 565
Description: The AP1 Reporter Kit is designed for monitoring the activity of the JNK signaling pathway and the transcriptional activity of AP1 in cultured cells. The kit contains a transfection-ready AP1 luciferase reporter vector. This reporter contains the firefly luciferase gene under the control of multimerized AP1 responsive elements located upstream of a minimal promoter. The AP1 reporter is premixed with a constitutively-expressing Renilla (sea pansy) luciferase vector that serves as an internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains the firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical for determining pathway-specific effects and the background luciferase activity.

Hh Signaling Pathway Antagonist

1659-1 each
EUR 216

Human Calcium Regulation Pathway

HCAR-I 1 set
EUR 657.6

GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway)

60655 2 vials
EUR 2275
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway.

Notch1 Pathway Reporter Kit (Human)

79503 500 rxns.
EUR 650
Description: Notch Pathway Reporter kit is designed for monitoring the activity of the Notch signaling pathway in cultured cells. The kit contains a transfection-ready expression vector for Human NOTCH1 that has a deletion of the entire extracellular domain, leaving the transmembrane and intracellular domains intact (Notch1DE). Inside the cells, the NOTCH1 DE is cleaved by γ-secretase and active NOTCH1 NICD is released into the nucleus. The kit also contains CSL (CBF1/RBP-Jk) luciferase reporter vector, which is a Notch pathway-responsive reporter. This reporter contains the firefly luciferase gene under the control of multimerized CSL responsive elements upstream of a minimal promoter. The CSL (CBF1/RBP-Jk) reporter is premixed with constitutively expressing Renilla (sea pansy) luciferase vector, which serves as an internal positive control for transfection efficiency._x000D_The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains a firefly luciferase gene under the control of a minimal promoter, but without any additional response elements. The negative control is critical for determining pathway specific effects and background luciferase activity._x000D_This kit contains the expression vector for Human Notch1DE. We also offer the Mouse Notch1DE expression vector (BPS Bioscience #60509), as well as a Mouse Notch1 NICD expression vector, which is constitutively active without processing by γ-secretase (BPS Bioscience #79504)._x000D_

TOR Signaling Pathway Detection Set

PSI-1805 1 Set
EUR 1287.6
Description: The mammalian Target of Rapamycin (TOR, also known as mTOR) is an evolutionarily conserved serine/threonine kinase that regulates cell growth and cell cycle progression through its ability to integrate signals from nutrient levels and growth factors. TOR regulation is accomplished through a network of various activators and repressors. It is phosphorylated by Akt, whose activity is indirectly inhibited by the lipid phosphatase PTEN. TOR is normally associated with the regulatory proteins RAPTOR, a scaffold protein whose binding by TOR substrates is necessary for effective TOR-catalyzed phosphorylation, and GΒL, which stimulates TOR’s kinase activity towards downstream proteins. It is further regulated by the proteins Rheb, TSC1 and TSC2, which act to modulate TOR activity. The downstream targets of TOR are thought to be the ribosomal protein S6 kinases and the eukaryotic initiation factor 4E binding proteins (4EBPs) whose activation leads to increased protein translation and cell growth.;;For images please see PDF data sheet

Human Cancer Pathway Primer Library

HCAN-I 1 set
EUR 657.6

TCF/LEF reporter-HEK293 cell line (Wnt Signaling Pathway, Lithium-Dependent)

60501 2 vials
EUR 2505
Description: The Wnt Signaling Pathway TCF/LEF Reporter (Luc) - HEK293 Cell Line is designed for monitoring the activity of the Wnt/b-catenin signaling pathway. The Wnt Signaling Pathway TCF/LEF Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of TCF/LEF responsive elements stably integrated into HEK293 cells. This cell line is validated for the response to the stimulation of mouse Wnt3a and to the treatment with an inhibitor of Wnt/b-catenin signaling pathway.

Human Hippo Signaling Primer Pathway

HHPO-I 1 set
EUR 657.6

FOXO Reporter Kit (PI3K/AKT Pathway)

60643 500 rxns.
EUR 565
Description: The FOXO Reporter kit is designed to monitor activity of the PI3K/AKT signaling pathway and the transcriptional activity of FOXO proteins in cultured cells. The kit contains the transfection-ready FOXO3 expression vector and the FOXO luciferase reporter vector, which is a PI3K/Akt pathway-responsive reporter. This reporter contains a firefly luciferase gene under the control of multimers of the FOXO responsive element located upstream of a minimal promoter. The FOXO reporter is premixed with a constitutively-expressing Renilla (sea pansy) luciferase vector, which serves as an internal control for the transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as negative control. The non-inducible luciferase vector also contains the firefly luciferase gene under the control of a minimal promoter, but without any additional response elements. The negative control is critical to determining pathway-specific effects and background luciferase activity.

Notch1 NICD Pathway Reporter Kit (Mouse)

79504 500 rxns.
EUR 590
Description: Notch Pathway Reporter kit is designed for monitoring the activity of the Notch signaling pathway in cultured cells. The kit contains a transfection-ready expression vector for Mouse NOTCH1 that has a deletion of the entire extracellular domain and transmembrane region (NOTCH1 NICD). Inside the cells, the NOTCH1 NICD is constitutively localized into the nucleus without needing to be cleaved by γ-secretase. The kit also contains CSL (CBF1/RBP-Jκ) luciferase reporter vector, which is a Notch pathway-responsive reporter. This reporter contains the firefly luciferase gene under the control of multimerized CSL responsive elements upstream of a minimal promoter. The CSL (CBF1/RBP-Jκ) reporter is premixed with constitutively expressing Renilla (sea pansy) luciferase vector, which serves as an internal positive control for transfection efficiency._x000D_The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains a firefly luciferase gene under the control of a minimal promoter, but without any additional response elements. The negative control is critical for determining pathway specific effects and background luciferase activity._x000D_This kit contains the expression vector for Mouse Notch1 NICD, which does not require γ-secretase processing to become active. We also offer the Mouse Notch1DE expression vector (BPS Bioscience #60509), as well as a Human Notch1DE expression vector (BPS Bioscience #79503), which are dependent on γ-secretase activity to become active.

Myc Reporter Kit (Myc Signaling Pathway)

60519 500 rxns.
EUR 625
Description: The Myc Pathway Reporter kit is designed for monitoring the activity of the Myc signaling pathway in cultured cells. The kit contains a transfection-ready expression vector for c- Myc and Myc luciferase reporter vector. Inside the cells, c-Myc will bind to Max, translocate to the nucleus, and induce expression of the Myc luciferase reporter vector. This reporter contains the firefly luciferase gene under the control of multimerized Myc responsive elements located upstream of a minimal promoter. The Myc reporter is premixed with constitutively-expressing Renilla (sea pansy) luciferase vector, which serves as an internal positive control for transfection efficiency._x000D_The kit also includes a non-inducible firefly luciferase vector premixed with constitutivelyexpressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains a firefly luciferase gene under the control of a minimal promoter, but without any additional response elements. The negative control is critical for determining pathway-specific effects and background luciferase activity.

Transfection Collection™ : CRE/CREB Transient Pack (cAMP/PKA Cell Signaling Pathway)

79267 500 rxns.
EUR 715
Description: The CRE/CREB Transient Pack is designed to provide the tools necessary for transiently transfecting and monitoring the activity of the cAMP/PKA signaling pathway in cultured cells. The kit contains transfection-ready vectors containing firefly luciferase as a cAMP/PKA pathway-responsive reporter and constitutively expressing Renilla luciferase as a transfection control. It also includes the Dual Luciferase detection reagents to detect both luciferase activities and specialized medium for growing and assaying HEK293 cells._x000D_The key to the CRE/CREB Transient Pack is the CRE/CREB luciferase reporter vector, which is a cAMP/PKA Cell Signaling Pathway-responsive reporter. This reporter contains the firefly luciferase gene under the control of multimerized cAMP response elements (CRE) located upstream of a minimal promoter. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase._x000D_The CRE reporter is premixed with constitutively-expressing Renilla (sea pansy) luciferase vector that serves as an internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with the constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains the firefly luciferase gene under the control of a minimal promoter, but without any additional response elements. The negative control is critical to determining pathway-specific effects and background luciferase activity._x000D_Additionally, the pack includes cell culture medium (BPS Medium 1) that has been optimized for use with HEK293 cells*. BPS Medium 1 includes MEM medium, 10% fetal bovine serum, 1% non-essential amino acids, sodium pyruvate, and 1% Pen/Strep. Finally, the pack provides the Dual Luciferase (Firefly-Renilla) Assay System. These luciferase reagents provide highly sensitive, stable detection of firefly luciferase activity and Renilla luciferase activity. The dual luciferase reagents can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required._x000D_* Other mammalian cell lines may also be used, but an alternate cell culture medium may be required for optimal cell growth.

ARE Reporter Kit (Nrf2 Antioxidant Pathway )

60514 500 rxns.
EUR 650
Description: The ARE Reporter kit is designed for monitoring the activity of the Nrf2 antioxidant pathway in cultured cells. The kit contains a transfection-ready ARE luciferase reporter vector, which is an Nrf2 pathway-responsive reporter. This reporter contains a firefly luciferase gene under the control of multimerized ARE responsive elements located upstream of a minimal promoter. The ARE reporter is premixed with a constitutively expressing Renilla (sea pansy) luciferase vector that serves as an internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively expressing Renilla luciferase vector as negative control. The non-inducible luciferase vector contains a firefly luciferase gene under the control of a minimal promoter, without any additional response elements. This negative control is critical to determining pathway-specific effects and background luciferase activity.

G-protein pathway suppressor 2 Antibody

20-abx137433
  • EUR 844.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 20 ug
  • 5 ug

Tissue Factor Pathway Inhibitor 2 Protein

20-abx263563
  • EUR 276.00
  • EUR 1930.80
  • EUR 393.60
  • 1 µg
  • 50 ug
  • 5 ug

STAT3 Reporter Kit (STAT3 Signaling Pathway)

79730 500 rxns.
EUR 640
Description: The STAT3 Reporter kit is designed for monitoring the activity of the STAT3 signaling pathway in cultured cells. The kit contains transfection-ready STAT3 luciferase reporter vector. This reporter contains a firefly luciferase gene under the control of STAT3-responsive element located upstream of a minimal promoter. The STAT3 reporter is premixed with constitutively expressing Renilla luciferase vector, which serves as an internal control for transfection efficiency._x000D_
The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains the firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical to determining pathway-specific effects and background luciferase activity.

Human Tissue factor pathway inhibitor (TFPI)

1-CSB-EP023437HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Tissue factor pathway inhibitor(TFPI),partial expressed in E.coli

Rabbit Tissue factor pathway inhibitor (TFPI)

1-CSB-BP023437RB
  • EUR 1008.00
  • EUR 398.40
  • EUR 2604.00
  • EUR 1362.00
  • EUR 1894.80
  • EUR 564.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in Baculovirus

Rabbit Tissue factor pathway inhibitor (TFPI)

1-CSB-YP023437RB
  • EUR 814.80
  • EUR 402.00
  • EUR 2606.40
  • EUR 1261.20
  • EUR 1730.40
  • EUR 522.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in Yeast

Rabbit Tissue factor pathway inhibitor (TFPI)

1-CSB-EP023437RB
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in E.coli

Rabbit Tissue factor pathway inhibitor (TFPI)

1-CSB-MP023437RB
  • EUR 466.80
  • EUR 1672.80
  • EUR 675.60
  • EUR 1230.00
  • 100ug
  • 1MG
  • 200ug
  • 500ug
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in Mammalian cell

TCF/LEF Reporter Kit (Wnt Signaling Pathway)

60500 500 rxns.
EUR 655
Description: The TCF/LEF Reporter kit is designed for monitoring the activity of Wnt / β-catenin signaling pathway in the cultured cells. The kit contains transfection-ready TCF/LEF luciferase reporter vector, which is a Wnt pathway-responsive reporter. This reporter contains a firefly luciferase gene under the control of multimerized TCF/LEF responsive element located upstream of a minimal promoter. The TCF/LEF reporter is premixed with constitutively-expressing Renilla luciferase vector that serves as internal control for transfection efficiency. _x000D_The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as negative control. The non-inducible luciferase vector contains a firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical to determining pathway specific effects and background luciferase activity. _x000D_

Tissue Factor Pathway Inhibitor (TFPI) Protein

20-abx261170
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

SRE Reporter Kit (MAPK/ERK Signaling Pathway )

60511 500 rxns.
EUR 595
Description: The SRE Reporter Kit is designed for monitoring the activity of the ERK signaling pathway and the transcriptional activity of SRF in cultured cells. The kit contains a transfection-ready SRE luciferase reporter vector, which is an ERK pathway-responsive reporter. This reporter contains the firefly luciferase gene under the control of multimerized SRE responsive elements located upstream of a minimal promoter. The SRE reporter is premixed with a constitutively-expressing Renilla (sea pansy) luciferase vector that serves as an internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains the firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical for determining pathway-specific effects and the background luciferase activity.

Tissue Factor Pathway Inhibitor (TFPI) Antibody

abx238634-100ug 100 ug
EUR 661.2

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx103325
  • EUR 376.80
  • EUR 159.60
  • EUR 994.80
  • EUR 526.80
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx103326
  • EUR 376.80
  • EUR 159.60
  • EUR 994.80
  • EUR 526.80
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx103328
  • EUR 510.00
  • EUR 159.60
  • EUR 1412.40
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx103329
  • EUR 510.00
  • EUR 159.60
  • EUR 1412.40
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx104947
  • EUR 376.80
  • EUR 159.60
  • EUR 994.80
  • EUR 526.80
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx174804
  • EUR 1011.60
  • EUR 526.80
  • 1 mg
  • 200 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx116110
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx129517
  • EUR 493.20
  • EUR 159.60
  • EUR 1362.00
  • EUR 661.20
  • EUR 376.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx132084
  • EUR 360.00
  • EUR 844.80
  • EUR 427.20
  • EUR 184.80
  • EUR 292.80
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx132085
  • EUR 393.60
  • EUR 1011.60
  • EUR 526.80
  • EUR 184.80
  • EUR 309.60
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx132086
  • EUR 360.00
  • EUR 844.80
  • EUR 427.20
  • EUR 184.80
  • EUR 292.80
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx323593
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Tissue Factor Pathway Inhibitor (TFPI) Antibody

abx433382-200ul 200 ul
EUR 460.8

Tissue Factor Pathway Inhibitor (TFPI) Antibody

20-abx001368
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
Curiously, DS therapy induced G2/M and G0/G1 cell cycle arrest within the MDA-MB-231 and MCF-7 cells, respectively. DS additionally elevated the phosphorylation of p38 and decreased the expression ranges of p-AKT and p-mTOR. These outcomes counsel that DS regulates the p38 mitogen-activated protein kinase and AKT/mTOR signaling pathways to cut back the proliferation of breast most cancers stem-like cells by cell cycle arrest. Subsequently, these findings counsel that DS could function a possible therapy candidate focusing on breast most cancers stem cells.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post